ZYMEWORKS INC (ZYME) Fundamental Analysis & Valuation

NASDAQ:ZYME • US98985Y1082

Current stock price

27.54 USD
-0.29 (-1.04%)
At close:
27.54 USD
0 (0%)
After Hours:

This ZYME fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ZYME Profitability Analysis

1.1 Basic Checks

  • ZYME had negative earnings in the past year.
  • ZYME had a negative operating cash flow in the past year.
  • ZYME had negative earnings in 4 of the past 5 years.
  • ZYME had negative operating cash flow in 4 of the past 5 years.
ZYME Yearly Net Income VS EBIT VS OCF VS FCFZYME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -23.41%, ZYME is in the better half of the industry, outperforming 71.84% of the companies in the same industry.
  • ZYME has a Return On Equity of -30.22%. This is in the better half of the industry: ZYME outperforms 75.15% of its industry peers.
Industry RankSector Rank
ROA -23.41%
ROE -30.22%
ROIC N/A
ROA(3y)-23.45%
ROA(5y)-21.12%
ROE(3y)-30.66%
ROE(5y)-30.36%
ROIC(3y)N/A
ROIC(5y)N/A
ZYME Yearly ROA, ROE, ROICZYME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60 -80

1.3 Margins

  • ZYME does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZYME Yearly Profit, Operating, Gross MarginsZYME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ZYME Health Analysis

2.1 Basic Checks

  • ZYME does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ZYME has more shares outstanding
  • The number of shares outstanding for ZYME has been increased compared to 5 years ago.
  • There is no outstanding debt for ZYME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ZYME Yearly Shares OutstandingZYME Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
ZYME Yearly Total Debt VS Total AssetsZYME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 12.07 indicates that ZYME is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of ZYME (12.07) is better than 83.50% of its industry peers.
  • ZYME has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.07
ROIC/WACCN/A
WACC9.51%
ZYME Yearly LT Debt VS Equity VS FCFZYME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • ZYME has a Current Ratio of 5.88. This indicates that ZYME is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 5.88, ZYME is in the better half of the industry, outperforming 61.36% of the companies in the same industry.
  • ZYME has a Quick Ratio of 5.88. This indicates that ZYME is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 5.88, ZYME is in the better half of the industry, outperforming 61.94% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.88
Quick Ratio 5.88
ZYME Yearly Current Assets VS Current LiabilitesZYME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ZYME Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 22.30% over the past year.
  • The Revenue has grown by 38.87% in the past year. This is a very strong growth!
  • Measured over the past years, ZYME shows a very strong growth in Revenue. The Revenue has been growing by 22.13% on average per year.
EPS 1Y (TTM)22.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-77.42%
Revenue 1Y (TTM)38.87%
Revenue growth 3Y-36.43%
Revenue growth 5Y22.13%
Sales Q2Q%-91.9%

3.2 Future

  • Based on estimates for the next years, ZYME will show a very strong growth in Earnings Per Share. The EPS will grow by 22.72% on average per year.
  • The Revenue is expected to grow by 26.30% on average over the next years. This is a very strong growth
EPS Next Y179.83%
EPS Next 2Y36.93%
EPS Next 3Y28.35%
EPS Next 5Y22.72%
Revenue Next Year138.52%
Revenue Next 2Y26.16%
Revenue Next 3Y14.84%
Revenue Next 5Y26.3%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ZYME Yearly Revenue VS EstimatesZYME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M
ZYME Yearly EPS VS EstimatesZYME Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

2

4. ZYME Valuation Analysis

4.1 Price/Earnings Ratio

  • ZYME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • With a Price/Forward Earnings ratio of 31.94, ZYME can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, ZYME is valued cheaper than 91.65% of the companies in the same industry.
  • ZYME's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 21.75.
Industry RankSector Rank
PE N/A
Fwd PE 31.94
ZYME Price Earnings VS Forward Price EarningsZYME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZYME Per share dataZYME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as ZYME's earnings are expected to grow with 28.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.93%
EPS Next 3Y28.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ZYME Dividend Analysis

5.1 Amount

  • No dividends for ZYME!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ZYME Fundamentals: All Metrics, Ratios and Statistics

ZYMEWORKS INC

NASDAQ:ZYME (4/30/2026, 8:24:44 PM)

After market: 27.54 0 (0%)

27.54

-0.29 (-1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)03-02
Earnings (Next)05-07
Inst Owners94.12%
Inst Owner Change0.02%
Ins Owners0.95%
Ins Owner Change4.66%
Market Cap2.03B
Revenue(TTM)105.97M
Net Income(TTM)-81.13M
Analysts85
Price Target40.88 (48.44%)
Short Float %6.69%
Short Ratio7.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.46%
Min EPS beat(2)-29.54%
Max EPS beat(2)20.62%
EPS beat(4)3
Avg EPS beat(4)31.26%
Min EPS beat(4)-29.54%
Max EPS beat(4)105.95%
EPS beat(8)5
Avg EPS beat(8)-13.02%
EPS beat(12)8
Avg EPS beat(12)-4.93%
EPS beat(16)11
Avg EPS beat(16)-0.06%
Revenue beat(2)0
Avg Revenue beat(2)-44.97%
Min Revenue beat(2)-81.84%
Max Revenue beat(2)-8.1%
Revenue beat(4)2
Avg Revenue beat(4)21.33%
Min Revenue beat(4)-81.84%
Max Revenue beat(4)146.55%
Revenue beat(8)3
Avg Revenue beat(8)0.68%
Revenue beat(12)6
Avg Revenue beat(12)8.84%
Revenue beat(16)7
Avg Revenue beat(16)1.1%
PT rev (1m)12.53%
PT rev (3m)12.53%
EPS NQ rev (1m)3.1%
EPS NQ rev (3m)-157.59%
EPS NY rev (1m)392.61%
EPS NY rev (3m)300.53%
Revenue NQ rev (1m)1.93%
Revenue NQ rev (3m)-49.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)23.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 31.94
P/S 19.17
P/FCF N/A
P/OCF N/A
P/B 7.56
P/tB 7.96
EV/EBITDA N/A
EPS(TTM)-1.08
EYN/A
EPS(NY)0.86
Fwd EY3.13%
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS1.44
BVpS3.64
TBVpS3.46
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -23.41%
ROE -30.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-23.45%
ROA(5y)-21.12%
ROE(3y)-30.66%
ROE(5y)-30.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.45%
Cap/Sales 2.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.88
Quick Ratio 5.88
Altman-Z 12.07
F-Score7
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)35.29%
Cap/Depr(5y)98.49%
Cap/Sales(3y)3.87%
Cap/Sales(5y)12.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-77.42%
EPS Next Y179.83%
EPS Next 2Y36.93%
EPS Next 3Y28.35%
EPS Next 5Y22.72%
Revenue 1Y (TTM)38.87%
Revenue growth 3Y-36.43%
Revenue growth 5Y22.13%
Sales Q2Q%-91.9%
Revenue Next Year138.52%
Revenue Next 2Y26.16%
Revenue Next 3Y14.84%
Revenue Next 5Y26.3%
EBIT growth 1Y23.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year171.56%
EBIT Next 3Y32.83%
EBIT Next 5YN/A
FCF growth 1Y68.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.01%
OCF growth 3YN/A
OCF growth 5YN/A

ZYMEWORKS INC / ZYME Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ZYMEWORKS INC (ZYME) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ZYME.


What is the valuation status of ZYMEWORKS INC (ZYME) stock?

ChartMill assigns a valuation rating of 2 / 10 to ZYMEWORKS INC (ZYME). This can be considered as Overvalued.


What is the profitability of ZYME stock?

ZYMEWORKS INC (ZYME) has a profitability rating of 1 / 10.


How financially healthy is ZYMEWORKS INC?

The financial health rating of ZYMEWORKS INC (ZYME) is 8 / 10.